GDF-8 Prodomain (Myostatin Propeptide)
Growth Differentiation Factor 8 Prodomain / Myostatin Propeptide
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
A natural protein fragment that blocks myostatin (a hormone that limits muscle growth), which may help preserve muscle mass in conditions that cause severe muscle wasting. No human clinical trials have been conducted, so its safety and effectiveness in people are not yet known.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Side effect data for the GDF-8 prodomain peptide specifically is extremely limited. No controlled human adverse-event dataset exists. The mouse Peptide-2 study (PMID 32519375) did not report a clear toxicity signal. Community and vendor sources report injection site welts, redness, and soreness as common occurrences. No FDA FAERS adverse event reports exist for this peptide. Broader myostatin pathway inhibition using ActRIIB-Fc decoy receptors (e.g., ACE-031) has been associated with telangiectasias and epistaxis due to off-target inhibition of BMP9/10. However, these effects are specific to the decoy receptor mechanism and may not apply to the prodomain peptide, which has greater selectivity for myostatin over activin and BMP ligands (PMID 32519375 showed Peptide-2 selectivity). Theoretical concerns about cardiac hypertrophy from myostatin inhibition exist given GDF-8 expression in heart tissue, but these have not been evaluated for the prodomain peptide specifically. Notably, Peptide-2 could not improve loss of heart weight in cachexia mice (PMID 32519375), which raises questions about cardiac effects.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-8]